Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose atorvastatin for prevention of contrast-induced nephropathy in high-risk PCI patients
ChiCTR-TRC-10001606Phase 4Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of atorvastatin in contrast-induced nephropathy (CIN) (3 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: alpha-microglobulin, microalbumin, transferrin, creatinine, cystatin C and 1 more. Started Jun 2011; status: recruiting.
02
Drugs
atorvastatin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on ChiCTR-TRC-10001606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10001606.